Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
243 hedge funds and large institutions have $8.57B invested in Verona Pharma in 2025 Q3 according to their latest regulatory filings, with 91 funds opening new positions, 48 increasing their positions, 79 reducing their positions, and 138 closing their positions.
55% more funds holding in top 10
Funds holding in top 10: 29 → 45 (+16)
31% more call options, than puts
Call options by funds: $78.3M | Put options by funds: $59.8M
19% more capital invested
Capital invested by funds: $7.18B → $8.57B (+$1.39B)
4.01% more ownership
Funds ownership: 89.23% → 93.24% (+4%)
17% less funds holding
Funds holding: 292 → 243 (-49)
34% less first-time investments, than exits
New positions opened: 91 | Existing positions closed: 138
39% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 79
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$553M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$447M |
| 3 |
HI
HBK Investments
Dallas,
Texas
|
+$445M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
+$364M |
| 5 |
BlackRock
New York
|
+$364M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$535M |
| 2 |
PA
Perceptive Advisors
New York
|
-$520M |
| 3 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$387M |
| 4 |
RI
RTW Investments
New York
|
-$289M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$212M |
VRNA Hedge Fund Activity: Q3 2025 in Review
243 institutional investors reported a position in Verona Pharma (VRNA) for Q3 2025, worth a combined $8.57B — up 19% from $7.18B a quarter earlier.
Sellers outnumbered buyers: 138 funds closed out of VRNA and 91 opened new positions — a net loss of 47 holders — while 79 trimmed existing stakes and 48 added.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $553M. The largest seller was Janus Henderson Group, cutting an estimated $535M.
- 243 institutional investors held Verona Pharma (VRNA) as of Q3 2025, down from 292 in Q2 2025.
- Funds reported $8.57B of Verona Pharma stock for Q3 2025, up 19% quarter-over-quarter.
- 91 funds opened new Verona Pharma positions in Q3 2025 and 138 closed out, a net change of -47 holders.
- The largest Verona Pharma buyer in Q3 2025 was Pentwater Capital Management, an estimated $553M added.
- The largest Verona Pharma seller in Q3 2025 was Janus Henderson Group, an estimated $535M sold.
Based on aggregated 13F filings for Q3 2025.